Abstract
Generalized pustular psoriasis (GPP) is a debilitating, and life-threatening systemic inflammatory disease with no approved therapies in the US or EU. Treatment of recurrent flares includes use of off-label systemic immunomodulators with potentially concerning safety risks. Imsidolimab (ANB019) is a high-affinity, humanized, anti-IL-36 receptor (IL-36R) monoclonal antibody that antagonizes IL-36 cytokine signaling that is being developed to treat GPP and other inflammatory dermatoses. A Phase 3, international, multicenter, randomized, double-blind, placebo-controlled study (ANB019-301) to evaluate the efficacy and safety of imsidolimab in adult subjects with active GPP was designed and initiated following completion of an open-label, single-arm, multiple-dose Phase 2 study (NCT03619902) that demonstrated rapid resolution of pustular eruptions and systemic symptoms in subjects with GPP flare.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
